Ampharco U.S.A Pharmaceutical – Trademark Portfolio
Entity Type: 09
Ampharco U.S.A Pharmaceutical holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include AMFAGOLD and AMPHARCO U.S.A. The owner is based in Dong Nai Province.
Nhon Trach 3 Industrial Park
Hiep Phuoc Commune, Nhon Trach Dist.
Dong Nai Province , VN
Showing of trademarks Trademarks
Trademark Classifications
Ampharco U.S.A Pharmaceutical's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Ampharco U.S.A Pharmaceutical have?
Ampharco U.S.A Pharmaceutical has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does Ampharco U.S.A Pharmaceutical file in?
Ampharco U.S.A Pharmaceutical files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Ampharco U.S.A Pharmaceutical's most well-known trademarks?
Ampharco U.S.A Pharmaceutical's registered trademark portfolio includes well-known marks such as AMFAGOLD and AMPHARCO U.S.A. These are among 3 currently registered trademarks in the portfolio.
What is Ampharco U.S.A Pharmaceutical's trademark registration success rate?
Ampharco U.S.A Pharmaceutical has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.